Osteopontin—A Master Regulator of Epithelial-Mesenchymal Transition
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Osteopontin (OPN) plays an important functional role in both physiologic and pathologic states. OPN is implicated in the progression of fibrosis, cancer, and metastatic disease in several organ systems. The epithelial-mesenchymal transition (EMT), first described in embryology, is increasingly being recognized as a significant contributor to fibrotic phenotypes and tumor progression. Several well-established transcription factors regulate EMT and are conserved across tissue types and organ systems, including TWIST, zinc finger E-box-binding homeobox (ZEB), and SNAIL-family members. Recent literature points to an important relationship between OPN and EMT, implicating OPN as a key regulatory component of EMT programs. In this review, OPN’s interplay with traditional EMT activators, both directly and indirectly, will be discussed. Also, OPN’s ability to restructure the tissue and tumor microenvironment to indirectly modify EMT will be reviewed. Together, these diverse pathways demonstrate that OPN is able to modulate EMT and provide new targets for directing therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 2×
“All ZEB proteins have two zinc finger clusters that bind to ZEB boxes of the regulatory regions of target genes [41].”
BackgroundKalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 2×
“Fibrosis is often the final outcome of chronic inflammatory diseases, and develops from the simultaneous activation of multiple profibrotic pathways [75].”
BackgroundSnail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121 · cited 1×
“The various molecular pathways that converge on Snail1 and Snail2 are well-described in several other reviews [41,58,59].”
BackgroundLiver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Direct regulation of TWIST by HIF-1α promotes metastasis
Yang, M.-H., Wu, M.-Z., Chiou, S.-H., Chen, P.-M., Chang, S.-Y., Liu, C.-J., Teng, S.-C., & Wu, K.-J. (2008) · Nature Cell Biology · doi:10.1038/ncb1691 · Cited by 1,345 · cited 1×
“Twist activity and promotes EMT [36].”
Ikenouchi, J., Matsuda, M., Furuse, M., & Tsukita, S. (2003) · Journal of Cell Science · doi:10.1242/jcs.00389 · Cited by 678
Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders
Piera-Velazquez, S., Li, Z., & Jimenez, S. A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.001 · Cited by 580
twist is a potential oncogene that inhibits apoptosis
Maestro, R., Tos, A. P. D., Hamamori, Y., Krasnokutsky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, D. H., & Hannon, G. J. (1999) · Genes & Development · doi:10.1101/gad.13.17.2207 · Cited by 516
Syn, W.-K., Choi, S. S., Liaskou, E., Karaca, G. F., Agboola, K. M., Oo, Y. H., Mi, Z., Pereira, T. A., Zdanowicz, M., Malladi, P., et al. (2011) · Hepatology · doi:10.1002/hep.23998 · Cited by 275 · cited 1×
“Clinically important relationships between OPN and GLI1 exist in nonalcoholic steatohepatitis (NASH) and melanoma, both of which demonstrate mechanisms OPN is able to modulate the EMT in the setting of fibrosis and cancer [67,68].”
BackgroundSelf-citationXiao, Z., Zhang, J., Peng, X., Dong, Y., Jia, L., Li, H., & Du, J. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.08.009 · Cited by 80 · cited 1×
“In kidney fibrosis, inhibition of Notch signaling results in decreased fibrosis and prevents TGF-β mediated EMT [96].”
BackgroundSelf-citation
Cited by
The role of osteopontin in the progression of solid organ tumour
Zhao, H., Chen, Q., Alam, A., Cui, J., Suen, K. C., Soo, A. P., Eguchi, S., Gu, J., & Ma, D. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0391-6 · Cited by 371
Osteopontin in Bone Metabolism and Bone Diseases
Si, J., Wang, C., Zhang, D., Wang, B., Hou, W., & Zhou, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.919159 · Cited by 301
Hatipoglu, O. F., Uctepe, E., Opoku, G., Wake, H., Ikemura, K., Ohtsuki, T., Inagaki, J., Gunduz, M., Gunduz, E., Watanabe, S., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111633 · Cited by 67
Drug Delivery Based on Nanotechnology for Target Bone Disease
Yang, X., Chen, S., Liu, X., Yu, M., & Liu, X. (2019) · Current Drug Delivery · doi:10.2174/1567201816666190917123948 · Cited by 15
Metadata
- Authors
- Kothari, A., Arffa, M., Chang, V., Blackwell, R., Syn, W.-K., Zhang, J., Mi, Z., & Kuo, P.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2016-03-23
- Volume
- 5
- Issue
- 4
- Pages
- 39
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2310005049
- Cited by
- 115
- References
- 12
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.